Haifa, Israel

Tal Bresler

This inventor holds 1 USPTO granted patent. Top assignee: Genegrafts Ltd.. Active years: 2012.


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tal Bresler: Innovator in Ion Channel Research

Introduction

Tal Bresler is a notable inventor based in Haifa, Israel. He has made significant contributions to the field of medical research, particularly in the area of ion channels. His work focuses on developing innovative solutions for medical conditions associated with ion channel insufficiency.

Latest Patents

Tal Bresler holds a patent for "Polynucleotides and polypeptide of human KV1.3, compositions comprising same and methods of using same." This patent describes an isolated polypeptide that includes a first amino acid sequence that is at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue, and a second amino acid sequence that is at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO: 2. The patent also provides polynucleotide sequences encoding this polypeptide and outlines its uses in treating medical conditions related to ion channel insufficiency.

Career Highlights

Tal Bresler is associated with Genegrafts Ltd., where he continues to advance his research and development efforts. His work has the potential to impact various medical treatments and improve patient outcomes.

Collaborations

Tal has collaborated with notable colleagues, including Yair Feld and Reem Miari. These partnerships enhance the research environment and contribute to the innovative projects at Genegrafts Ltd.

Conclusion

Tal Bresler is a prominent figure in the field of ion channel research, with a focus on developing solutions for medical conditions. His patent and ongoing work at Genegrafts Ltd. highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…